Boosting resilience with an electronic frailty index guided care plan

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective single-arm intervention enrolling adults aged 65 and older with active cancer who are pre-frail or frail by an EHR-based electronic frailty index (eFI) and are planning to start outpatient chemotherapy. After a baseline assessment participants receive their eFI results, are offered referrals to supportive care services, and complete weekly symptom reporting via electronic surveys plus a research nurse phone call for 12 weeks. Follow-up assessments occur at 12 weeks, and a subset of patients and treating providers will be invited for interviews to collect feedback on barriers and facilitators. The study is conducted at participating Atrium Health sites in North Carolina.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Patients with cancer:

* Ability to understand and willingness to sign an IRB-approved informed consent
* Age ≥ 65 years at the time of enrollment.
* Planned to initiate an outpatient chemotherapy regimen (including myelosuppressive biologic/immune therapies) for cancer treatment (any type or stage), either as an initial therapy or as a new line of therapy, with curative or palliative intent.
* eFI pre-frail or frail status (available in EHR; defined as eFI \> 0.10) within 30 days before enrollment.
* Ability to read and understand the English language

Providers:

* Treating medical oncologist of at least one patient participant who enrolled on to the study and completed baseline assessment.

Exclusion Criteria:

Patients:

* Documented physical or psychological comorbidity that would limit participant's ability to understand or comply with study procedures for the entire length of the study per the enrolling investigator.
* Chemotherapy planned at a facility outside the Atrium Health system.
* Currently receiving chemotherapy (defined as planned to continue an on-going treatment rather than starting a new regimen).

Where it's running

• Levine Cancer Institute
  Charlotte, North Carolina, United States Recruiting
• Atrium Health Wake Forest Baptist Comprehensive Cancer Center
  Winston-Salem, North Carolina, United States Recruiting

Study contacts

• Principal investigator: Heidi Klepin, MD — Wake Forest University Health Sciences
• Study coordinator: James Morgan
• Email: james.morgan@advocatehealth.org
• Phone: 336-702-4491

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Investigating dizziness and muscle weakness in older colorectal cancer patients during chemotherapy

  This study is testing whether a special exercise program and health check-ups can help older colorectal cancer patients feel less dizzy and improve their balance during chemotherapy.

  Recruiting Copenhagen University Hospital, Rigshospitalet · Copenhagen and 1 other locations · NCT05710809

• Gait Changes in Breast Cancer Patients Receiving Chemotherapy

  This study tests how chemotherapy affects walking and balance in women with breast cancer.

  Recruiting Cairo University · Cairo, Cairo Governorate · NCT07894133

• Targeted Induction Therapy for Stage III Unresectable EGFR Mutant NSCLC

  This trial tests a targeted induction approach using fumetinib with platinum-based chemotherapy and concurrent radiochemotherapy in adults with unresectable stage III EGFR-mutant NSCLC to see if this combo can improve outcomes before possible surgery.

  Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT07742332

• VR-guided mindfulness for anxiety, sleep, comfort, and fatigue in women with breast cancer undergoing chemotherapy

  This study tests whether a virtual reality–based mindfulness program can help women with breast cancer feel less anxious, sleep better, feel more comfortable, and have less fatigue during chemotherapy.

  Recruiting Hacettepe University · Ankara, Ankara · NCT07731477

• Using plasma ctDNA methylation to guide adjuvant chemotherapy for high-risk T3N0 colorectal cancer

  This will test whether a blood ctDNA methylation test can help choose stronger chemotherapy after surgery for people with high-risk T3N0 (stage II) colorectal cancer who are ctDNA-positive one month after surgery.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07562711

• Plasma ctDNA methylation-guided adjuvant chemotherapy for people with T4N0 and low‑risk stage III colorectal cancer.

  This trial will test whether using a blood test (plasma ctDNA methylation) to guide 3 vs 6 months of adjuvant chemotherapy or to switch regimens helps people with T4N0 or low‑risk stage III colorectal cancer after surgery.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07562503

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.